HomeCompareFGMNX vs MRK

FGMNX vs MRK: Dividend Comparison 2026

FGMNX yields 3.31% · MRK yields 2.76%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MRK wins by $32.0K in total portfolio value
10 years
FGMNX
FGMNX
● Live price
3.31%
Share price
$10.37
Annual div
$0.34
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$24.8K
Annual income
$410.16
Full FGMNX calculator →
MRK
Merck & Co. Inc.
● Live price
2.76%
Share price
$120.31
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$56.8K
Annual income
$9,798.13
Full MRK calculator →

Portfolio growth — FGMNX vs MRK

📍 MRK pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodFGMNXMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, FGMNX + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
FGMNX pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

FGMNX
Annual income on $10K today (after 15% tax)
$281.67/yr
After 10yr DRIP, annual income (after tax)
$348.64/yr
MRK
Annual income on $10K today (after 15% tax)
$234.56/yr
After 10yr DRIP, annual income (after tax)
$8,328.41/yr
At 15% tax rate, MRK beats the other by $7,979.77/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of FGMNX + MRK for your $10,000?

FGMNX: 50%MRK: 50%
100% MRK50/50100% FGMNX
Portfolio after 10yr
$40.8K
Annual income
$5,104.15/yr
Blended yield
12.52%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

FGMNX
No analyst data
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+6.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

FGMNX buys
0
MRK buys
0
No recent congressional trades found for FGMNX or MRK in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricFGMNXMRK
Forward yield3.31%2.76%
Annual dividend / share$0.34$3.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%32.7%
Portfolio after 10y$24.8K$56.8K
Annual income after 10y$410.16$9,798.13
Total dividends collected$3.7K$28.9K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: FGMNX vs MRK ($10,000, DRIP)

YearFGMNX PortfolioFGMNX Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$11,031$331.38$11,206$366.19$175.00MRK
2$12,145$341.64$12,650$502.35$505.00MRK
3$13,347$351.53$14,407$694.19$1.1KMRK
4$14,642$361.04$16,585$967.82$1.9KMRK
5$16,037$370.17$19,342$1,363.89$3.3KMRK
6$17,539$378.91$22,913$1,947.19$5.4KMRK
7$19,154$387.28$27,662$2,823.89$8.5KMRK
8$20,890$395.27$34,159$4,173.35$13.3KMRK
9$22,755$402.89$43,337$6,308.80$20.6KMRK
10$24,758$410.16$56,776$9,798.13$32.0KMRK

FGMNX vs MRK: Complete Analysis 2026

FGMNXStock

The fund normally invests at least 80% of assets in Ginnie Maes and repurchase agreements for Ginnie Maes. It invests in other U.S. government securities and instruments related to U.S. government securities. The fund invests in U.S. government securities issued by entities that are chartered or sponsored by Congress but whose securities are neither issued nor guaranteed by the U.S. Treasury. It seeks to have similar overall interest rate risk to the Bloomberg Barclays GNMA Index.

Full FGMNX Calculator →

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this FGMNX vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

FGMNX vs SCHDFGMNX vs JEPIFGMNX vs OFGMNX vs KOFGMNX vs MAINFGMNX vs JNJFGMNX vs ABBVFGMNX vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.